Hemogenyx Pharmaceuticals is a UK-based preclinical-stage biotech company focused on developing therapies and treatments for blood diseases, particularly for the bone marrow/hematopoietic stem cell transplant market. The company's products target acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, amongst others. Hemogenyx is also developing chimeric antigen receptor T-cells for use in immunotherapy, and stem cell therapy products for bone marrow transplants. Hemogenyx has a collaboration with GlobalCo and was incorporated in 2013.
Hemogenyx Pharmaceuticals Plc's ticker is HEMO
The company's shares trade on the LSE stock exchange
They are based in London, England
There are 1-10 employees working at Hemogenyx Pharmaceuticals Plc
It is https://hemogenyx.com/
Hemogenyx Pharmaceuticals Plc is in the Healthcare sector
Hemogenyx Pharmaceuticals Plc is in the Biotechnology industry
The following five companies are Hemogenyx Pharmaceuticals Plc's industry peers: